Treatment of irritable bowel syndrome with lacteol fort: A randomized, double-blind, cross-over trial

Georges M. Halpern, Thomas P Prindiville, Marlese Blankenburg, Thomas Hsia, M. Eric Gershwin

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Objective: To assess the efficacy of Lacteol Fort, an antidiarrheal drug, in patients suffering from the chronic intestinal disease known as irritable bowel syndrome (IBS). Design: The randomized, double-blind, cross-over trial versus placebo was carried out from 1992 to 1994. This trial consisted of administering a 6-wk treatment with a first drug (Lacteol Fort or placebo), followed by a wash-out period of 2 wk, and then the administration of a second drug for a further 6 wk (placebo or Lacteol Fort). Among the 29 patients eligible after recruitment, 18 adults with well documented lBS fulfilled the inclusion criteria. Four patients were dropped for loss of materials used in the study and seven for lack of compliance. The patient's initial state was assessed using a questionnaire relating to six criteria: abdominal pain, bloating or gas, daily number of stools, consistency, mucus content, and general physical state. During the treatment, these criteria were evaluated daily by the patients themselves. Results: All investigated criteria were scored, and then a daily mean index was calculated. The statistical analysis of the daily mean index values showed that the number of patients (nine cases) obtaining better results with Lacteol Fort than with placebo was statistically significant (p = 0.018). Conclusions: This double-blind, placebo-controlled, cross-over trial demonstrated that Lacteol Fort leads to a statistically significant therapeutic benefit in 50% of patients, when taking into consideration all of the six selected clinical criteria considered representative of IBS.

Original languageEnglish (US)
Pages (from-to)1579-1585
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume91
Issue number8
StatePublished - Aug 1996

Fingerprint

Irritable Bowel Syndrome
Cross-Over Studies
Placebos
Therapeutics
Antidiarrheals
Intestinal Diseases
Mucus
Lacteol
Pharmaceutical Preparations
Abdominal Pain
Compliance
Chronic Disease
Gases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of irritable bowel syndrome with lacteol fort : A randomized, double-blind, cross-over trial. / Halpern, Georges M.; Prindiville, Thomas P; Blankenburg, Marlese; Hsia, Thomas; Gershwin, M. Eric.

In: American Journal of Gastroenterology, Vol. 91, No. 8, 08.1996, p. 1579-1585.

Research output: Contribution to journalArticle

@article{6b30be9cd26c4806b87c91275b6fc6cc,
title = "Treatment of irritable bowel syndrome with lacteol fort: A randomized, double-blind, cross-over trial",
abstract = "Objective: To assess the efficacy of Lacteol Fort, an antidiarrheal drug, in patients suffering from the chronic intestinal disease known as irritable bowel syndrome (IBS). Design: The randomized, double-blind, cross-over trial versus placebo was carried out from 1992 to 1994. This trial consisted of administering a 6-wk treatment with a first drug (Lacteol Fort or placebo), followed by a wash-out period of 2 wk, and then the administration of a second drug for a further 6 wk (placebo or Lacteol Fort). Among the 29 patients eligible after recruitment, 18 adults with well documented lBS fulfilled the inclusion criteria. Four patients were dropped for loss of materials used in the study and seven for lack of compliance. The patient's initial state was assessed using a questionnaire relating to six criteria: abdominal pain, bloating or gas, daily number of stools, consistency, mucus content, and general physical state. During the treatment, these criteria were evaluated daily by the patients themselves. Results: All investigated criteria were scored, and then a daily mean index was calculated. The statistical analysis of the daily mean index values showed that the number of patients (nine cases) obtaining better results with Lacteol Fort than with placebo was statistically significant (p = 0.018). Conclusions: This double-blind, placebo-controlled, cross-over trial demonstrated that Lacteol Fort leads to a statistically significant therapeutic benefit in 50{\%} of patients, when taking into consideration all of the six selected clinical criteria considered representative of IBS.",
author = "Halpern, {Georges M.} and Prindiville, {Thomas P} and Marlese Blankenburg and Thomas Hsia and Gershwin, {M. Eric}",
year = "1996",
month = "8",
language = "English (US)",
volume = "91",
pages = "1579--1585",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Treatment of irritable bowel syndrome with lacteol fort

T2 - A randomized, double-blind, cross-over trial

AU - Halpern, Georges M.

AU - Prindiville, Thomas P

AU - Blankenburg, Marlese

AU - Hsia, Thomas

AU - Gershwin, M. Eric

PY - 1996/8

Y1 - 1996/8

N2 - Objective: To assess the efficacy of Lacteol Fort, an antidiarrheal drug, in patients suffering from the chronic intestinal disease known as irritable bowel syndrome (IBS). Design: The randomized, double-blind, cross-over trial versus placebo was carried out from 1992 to 1994. This trial consisted of administering a 6-wk treatment with a first drug (Lacteol Fort or placebo), followed by a wash-out period of 2 wk, and then the administration of a second drug for a further 6 wk (placebo or Lacteol Fort). Among the 29 patients eligible after recruitment, 18 adults with well documented lBS fulfilled the inclusion criteria. Four patients were dropped for loss of materials used in the study and seven for lack of compliance. The patient's initial state was assessed using a questionnaire relating to six criteria: abdominal pain, bloating or gas, daily number of stools, consistency, mucus content, and general physical state. During the treatment, these criteria were evaluated daily by the patients themselves. Results: All investigated criteria were scored, and then a daily mean index was calculated. The statistical analysis of the daily mean index values showed that the number of patients (nine cases) obtaining better results with Lacteol Fort than with placebo was statistically significant (p = 0.018). Conclusions: This double-blind, placebo-controlled, cross-over trial demonstrated that Lacteol Fort leads to a statistically significant therapeutic benefit in 50% of patients, when taking into consideration all of the six selected clinical criteria considered representative of IBS.

AB - Objective: To assess the efficacy of Lacteol Fort, an antidiarrheal drug, in patients suffering from the chronic intestinal disease known as irritable bowel syndrome (IBS). Design: The randomized, double-blind, cross-over trial versus placebo was carried out from 1992 to 1994. This trial consisted of administering a 6-wk treatment with a first drug (Lacteol Fort or placebo), followed by a wash-out period of 2 wk, and then the administration of a second drug for a further 6 wk (placebo or Lacteol Fort). Among the 29 patients eligible after recruitment, 18 adults with well documented lBS fulfilled the inclusion criteria. Four patients were dropped for loss of materials used in the study and seven for lack of compliance. The patient's initial state was assessed using a questionnaire relating to six criteria: abdominal pain, bloating or gas, daily number of stools, consistency, mucus content, and general physical state. During the treatment, these criteria were evaluated daily by the patients themselves. Results: All investigated criteria were scored, and then a daily mean index was calculated. The statistical analysis of the daily mean index values showed that the number of patients (nine cases) obtaining better results with Lacteol Fort than with placebo was statistically significant (p = 0.018). Conclusions: This double-blind, placebo-controlled, cross-over trial demonstrated that Lacteol Fort leads to a statistically significant therapeutic benefit in 50% of patients, when taking into consideration all of the six selected clinical criteria considered representative of IBS.

UR - http://www.scopus.com/inward/record.url?scp=0029738351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029738351&partnerID=8YFLogxK

M3 - Article

C2 - 8759665

AN - SCOPUS:0029738351

VL - 91

SP - 1579

EP - 1585

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -